Steigerwald Gordon & Koch’s Ligand Pharmaceuticals LGND Stock Holding History

Steigerwald Gordon & Koch’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$495K	Hold	1,566	–	–	0.05%	87
2026 Q1	$313K	Hold	1,566	–	–	0.03%	107
2025 Q4	$296K	Hold	1,566	–	–	0.03%	112
2025 Q3	$277K	Buy	+1,566	New	+$233K	0.03%	114
2022 Q1	–	Sell	-2,510	Closed	-$242K	–	120
2021 Q4	$242K	Hold	2,510	–	–	0.04%	104
2021 Q3	$218K	Hold	2,510	–	–	0.04%	109
2021 Q2	$205K	Hold	2,510	–	–	0.03%	112
2021 Q1	$239K	Buy	+2,510	New	+$237K	0.04%	93
2019 Q1	–	Sell	-2,510	Closed	-$213K	–	85
2018 Q4	$213K	Hold	2,510	–	–	0.06%	80
2018 Q3	$430K	Hold	2,510	–	–	0.11%	59
2018 Q2	$324K	Buy	+2,510	New	+$280K	0.09%	68
2018 Q1	–	Sell	-2,510	Closed	-$214K	–	85
2017 Q4	$214K	Buy	+2,510	New	+$218K	0.06%	79
2017 Q3	–	Sell	-2,671	Closed	-$202K	–	90
2017 Q2	$202K	Buy	+2,671	New	+$187K	0.06%	83
2016 Q4	–	Sell	-3,203	Closed	-$204K	–	88
2016 Q3	$204K	Hold	3,203	–	–	0.07%	67
2016 Q2	$238K	Hold	3,203	–	–	0.09%	59
2016 Q1	$214K	Hold	3,203	–	–	0.08%	58
2015 Q4	$217K	Buy	+3,203	New	+$198K	0.09%	54
2015 Q2	–	Sell	-16,880	Closed	-$328K	–	52
2015 Q1	$328K	Buy	+16,880	New	+$647K	0.15%	44

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steigerwald Gordon & Koch's LGND Position: Q2 2026 in Review

Steigerwald Gordon & Koch held its Ligand Pharmaceuticals (LGND) position steady in Q2 2026 at 1,566 shares worth $495K. The position accounts for 0.05% of the portfolio, ranked #87.

Steigerwald Gordon & Koch first reported a position in LGND in Q1 2015 and has held it in 18 quarters since. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Steigerwald Gordon & Koch held 1,566 shares of Ligand Pharmaceuticals worth $495K as of Q2 2026.
Steigerwald Gordon & Koch left its Ligand Pharmaceuticals share count unchanged in Q2 2026.
Ligand Pharmaceuticals made up 0.05% of Steigerwald Gordon & Koch's portfolio in Q2 2026, its #87 holding.
Steigerwald Gordon & Koch first reported a position in Ligand Pharmaceuticals in Q1 2015 and has held it in 18 quarters since.
417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Steigerwald Gordon & Koch's 13F filing for Q2 2026, filed 23 Jul 2026.